Hofseth BioCare

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Hofseth BioCare has already paid €0.046 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Hofseth BioCare had revenue of €7.53m and net profit of -€1.18m

(EUR)	September 2026	YoY
Revenue	7.53m	60.84%
Gross profit	1.3m	21.77%
Net profit	-1.18m	51.11%
EBITDA	260.84k	123.73%

Fundamentals

Metric	Value
Market capitalization	€43.23m
Number of shares	411m
52-week high/low	€0.19 - €0.0948
Dividends	No
Beta	0.25
P/E ratio	-3.81
PEG ratio	-0.81
P/B ratio	-316.73
P/S ratio	1.72

Company profile

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.